

# Clinical Phase 1 Development of SKL27969, a Novel Brain Penetrating PRMT5 Inhibitor

SK Biopharmaceuticals Co., Ltd.



ONCOLOGY	Phase I
Product Type	Small Molecule
Indication	Advanced Solid Tumor (i.g. GBM, NSCLC, and TNBC)
Target	Protein arginine methyl-transferase 5 (PRMT5)
MoA(Mechanism of Action)	A potent and selective SAM-cooperative PRMT5 inhibition
Competitiveness	<ul style="list-style-type: none"> <li>• Excellent brain penetration and high tumor to plasma ratio</li> <li>• Strong anti-tumor efficacy in various tumor models</li> <li>• Potent and prolonged PRMT5 inhibition</li> <li>• Synergistic effects with standard cancer therapeutics</li> <li>• Orally bioavailable and favorable safety/toxicity profiles</li> </ul>
Development Stage	Phase I (NCT05388435)
Route of Administration	Oral Administration